AcuCort has received a new order for Zeqmelit® from its Nordic distribution partner, Unimedic Pharma. The order covers the Nordic market.
Zeqmelit® was launched in Sweden, Norway, and Finland in September 2024, followed by Denmark in the summer of 2025. The new order from Unimedic Pharma, AcuCort's Nordic distribution partner, is for the Nordic market.
"The launch of Zeqmelit® is developing in line with expectations for a newly introduced pharmaceutical, which is very encouraging," says AcuCort's CEO, Jonas Jönmark.
The order is valued at EUR 112,000 and is expected to have a positive impact on AcuCort's financial performance during the second quarter 2026.
For further information:
Jonas Jönmark, CEO, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.se
About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.